News

The drug was not evaluated in patients with MCD who are HIV positive or HHV-8 positive because it did not bind to virally produced interleukin-6 (IL-6) in a

Pure is part of the Elsevier Research Intelligence portfolio of tools and services. Over the years, UrFU, one of the leading Russian universities, has focused on increasing the

Both the companies’ have not disclosed the financial terms of the agreement. In July 2013, both the firms have entered into their first manufacturing agreement to collaborate in

The NDA submission was based on data from the largest Phase III program in GT1 patients conducted to date, with six Phase III studies that included over 2,300

The recently issued patent, which is the second US patent issued to ProLynx, focuses on drugs covalently coupled via the company’s patented beta-eliminative linkers to multiple sites on

The team, led by Dr Matthew Hardman have been awarded an MRC Industry Collaboration Agreement (MICA) grant from the UK Medical Research Council to help fund the investigations.

This patent expands the intellectual property for the Company’s opioid abuse deterrent technology. Elite now has three US patents and one Canadian patent issued in this area with

The early administration of plasma has an important role in reducing battlefield mortality rates, and therefore the USAMMDA has prioritized the development of a freeze-dried plasma product. Currently,

Bayer is developing Ciprofloxacin DPI for NCFB patients with respiratory bacterial pathogens, including Pseudomonas aeruginosa, to reduce the frequency of acute exacerbations. These patients suffer from frequent severe